Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Pharmaron Beijing Co Ltd (Pharmaron) is a life science service company that offers a comprehensive range of research, development, and manufacturing services. Its services include laboratory services, chemistry, manufacturing and controls services, clinical development services, and biologics and cell and gene therapy services. The company’s laboratory services include laboratory chemistry, structural biology, in vitro biology, in vivo pharmacology, DMPK, safety assessment, bioanalysis, integrated drug discovery and medical device testing. It also offers biologics laboratory services, biologics CDMO, cell and gene therapy laboratory services and gene therapy CDMO services. The company operates in China, the U.S, the U.K, Japan, and China. Pharmaron is headquartered in Beijing, China.
Headquarters
China
Address
No. 6, Taihe Road, Beijing Economic-Technological Development Area, 100176
Website
www.pharmaron.cn
Telephone
86 10 57330087
No of Employees
25,088
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300759 (SHE)
Revenue (2024)
$2.0B
14.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-7.2%
(2024 vs 2023)
Market Cap*
$7.3B
Net Profit Margin (2024)
XYZ
-19.2%
(2024 vs 2023)
* As of and is in US$
Pharmaron Beijing Co Ltd premium industry data and analytics
Products and Services
| Services |
|---|
| Laboratory |
| Laboratory Chemistry Services |
| Structural Biology Services |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company signed a share purchase agreement to acquire an 82.54% stake in Biortus Biosciences Co Ltd. |
| 2023 | Plans/Strategy | In October, Pharmaron Chemicals plans to invest US$10.5 million in Rxilient Biohub Pte. Ltd. with China Medical System, Rxilient Health Pte. Ltd and Healthy Goal Limited to expand pharmaceutical CDMO service capabilities in Southeast Asia. |
| 2023 | Financing Agreements | In March, the company announced that Gene Therapy CDMO secured a grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM. |
Competitor Comparison
| Key Parameters | Pharmaron Beijing Co Ltd | CSPC Pharmaceutical Group Ltd | Accela ChemBio Inc | BioDuro LLC | Kingchem Liaoning Chemical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | United States of America | United States of America | China |
| City | Beijing | Shijiazhuang | San Diego | Irvine | Fuxin |
| State/Province | Beijing | Hebei | California | California | Liaoning |
| No. of Employees | 25,088 | 19,700 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Boliang Lou, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2016 | 62 |
| Li Chengzong | Chief Financial Officer; Director; Secretary | Executive Board | 2025 | 48 |
| Lou Xiaoqiang | Chief Operating Officer; Director; President | Executive Board | 2016 | 57 |
| Hua Yang, Ph.D. | Chief Science Officer; Chief Scientific Officer | Senior Management | 2016 | - |
| Connie Sun, Ph.D. | Head - Business Development and Small Molecules; Senior Vice President | Senior Management | 2009 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer